Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Adherium Ltd. ( (AU:ADR) ) is now available.
Adherium Limited, a Melbourne-based digital respiratory management specialist, develops the FDA-cleared Hailie Smartinhaler platform that connects respiratory medications to mobile and desktop apps for remote monitoring. The company’s technology is designed to give healthcare providers detailed visibility into patients’ medication use and adherence patterns, facilitating value-based care and reimbursement for qualified patient populations.
In a recent investor webinar, Adherium reported strong growth in its remote patient monitoring channel, with device shipments rising from 351 in Q4 FY2025 to 2,149 in Q2 FY2026 and RPM revenue increasing from $50,800 to $171,000, positioning this segment as the engine for larger value-based contracts with U.S. insurers. Interim data from the landmark iCARE study showed Hailie users with asthma and COPD achieving adherence rates of 64% and 67% versus baseline levels of about 20%, and, together with a recently completed $6.7 million capital raise and additional retail offer, the results underscore both the clinical and economic potential of Adherium’s platform while strengthening its funding base for the next growth phase.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australia-based provider of integrated digital health solutions focused on respiratory care, and a global leader in connected respiratory medical devices with more than 180,000 units sold worldwide. Its FDA-cleared Hailie Smartinhaler platform and associated apps, integration tools, and sensors enable clinicians, healthcare providers, and patients to remotely monitor inhaler use and adherence, supporting reimbursed patient management in markets such as the U.S.
Technical Sentiment Signal: Sell
Current Market Cap: A$21.64M
See more data about ADR stock on TipRanks’ Stock Analysis page.